Gilead Sciences, Inc. Stock price

Equities

GILD

US3755581036

Pharmaceuticals

Real-time Estimate Cboe BZX 12:37:31 2023-12-07 pm EST Intraday chart for Gilead Sciences, Inc. 5-day change 1st Jan Change
78.32 USD -1.30% +2.61% -8.44%
Sales 2023 * 27.05B Sales 2024 * 27.61B Capitalization 98.89B
Net income 2023 * 5.89B Net income 2024 * 6.66B EV / Sales 2023 *
4,20x
Net Debt 2023 * 14.76B Net Debt 2024 * 9.78B EV / Sales 2024 *
3,94x
P/E ratio 2023 *
16,9x
P/E ratio 2024 *
14,6x
Employees 17,000
Yield 2023 *
3,81%
Yield 2024 *
4,01%
Free-Float 99.88%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.79%
1 week+2.55%
Current month+2.55%
1 month-2.56%
3 months+6.23%
6 months+3.25%
Current year-8.50%
More quotes
1 week
76.20
Extreme 76.2
80.18
1 month
73.99
Extreme 73.99
80.18
Current year
72.87
Extreme 72.8659
88.29
1 year
72.87
Extreme 72.8659
89.74
3 years
56.56
Extreme 56.56
89.74
5 years
56.56
Extreme 56.56
89.74
10 years
56.56
Extreme 56.56
123.37
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 2019
Director of Finance/CFO 53 2015
Chief Tech/Sci/R&D Officer - 2021
Members of the board TitleAgeSince
Director/Board Member 68 2020
Director/Board Member 70 2017
Director/Board Member 68 2009
More insiders
Date Price Change Volume
23-12-07 78.54 -1.03% 3 057 594
23-12-06 79.36 +0.43% 5,745,464
23-12-05 79.02 +0.87% 6,277,013
23-12-04 78.34 +0.89% 8,194,691
23-12-01 77.65 +1.37% 5,400,471

Delayed Quote Nasdaq, December 07, 2023 at 10:55 am EST

More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
79.36USD
Average target price
90.39USD
Spread / Average Target
+13.90%
Consensus
1st Jan change Capi.
-8.50% 98 886 M $
+58.87% 530 B $
+41.81% 438 B $
-12.20% 377 B $
-6.34% 268 B $
-9.16% 258 B $
-14.20% 230 B $
+0.61% 200 B $
-10.39% 198 B $
-44.32% 163 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Gilead Sciences, Inc. - Nasdaq
As early as today, start finding the best investment opportunities!
Optimize my profits
fermer